MTOR and thyroid cancer: In summary, the dual PI3K/mTOR inhibitor NVP-BEZ235 has a therapeutic effect on thyroid cancer, among which thyroid tumors with mutant p53 are critically dependent on the response of GSK3β/β-catenin signaling, up-regulating p21 and then inducing G0/G1 cell cycle arrest in human thyroid cancer.